
Jubilant Ingrevia Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- Jubilant Ingrevia targets a 3x revenue increase and 4x EBITDA growth by FY'29 from the FY'24 base (Rs. 4,200 crore revenue).
- Specialty Chemicals and Nutrition segments are expected to form over 75% of revenue with continued volume growth.
- Specialty Chemical revenues grew 13% YoY with volume growth around 25%.
- Nutrition business revenue increased 12% YoY driven by higher sales volumes (animal and human-grade Niacinamide) and rising prices.
- Agrochemical demand is recovering with volumes increasing after destocking; pricing shows pockets of improvement.
- The company anticipates incremental CAPEX of Rs. 600-800 crore annually for the next 3 years to support growth, mostly funded via internal accruals.
- CDMO contracts (including a $300 million, 5-year agrochemical contract) signal significant volume ramp-up from FY'26 onwards.
- Continued focus on high-margin Specialty and Nutrition products implies improving revenue mix and margin expansion.
See what Jubilant Ingrevia management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Jubilant Ingrevia plans incremental CAPEX of Rs. 600 to 800 crore per annum over the next three years, mainly focused on Specialty and Nutrition segments.
- The company intends to fund most of this CAPEX through internal accruals and EBITDA generated from existing operations.
- Current debt levels stand around Rs. 650-700 crore, with no plans to exceed Rs. 900-1,000 crore.
- Debt coverage ratio is internally targeted to remain under 1.4x.
- If needed, marginal increase in debt may be considered but no significant new debt or equity fundraising is planned at this stage.
See what Jubilant Ingrevia management said on order book — free account, 30 seconds.
Capex plans
Yes- Wave-I CAPEX of Rs. 2,000 crore mostly completed with investments in Specialty and Nutrition segments.
- Upcoming Wave-II CAPEX planned at Rs. 2,000 to 2,500 crore over the next 3 years (~Rs. 700-800 crore annually).
- 100% of Wave-II investment to focus on Specialty and Nutrition portfolios.
- CAPEX geared towards CDMO opportunities in agro, pharma, semiconductors; multipurpose plants for pyridine and diketene derivatives.
- Additional investments in expansion and modification of agro intermediate and active plants (~Rs. 300 crore) for $300 million CDMO contract.
- Strategy-led incremental CAPEX expected to be largely funded by internal accruals; aim to keep debt below Rs. 900-1,000 crore with coverage ratio under 1.4x.
- New projects, including food and cosmetic grade Niacinamide plant, slated for commissioning in Q3 FY'25; more multipurpose plants planned.
- Continuous focus on agile, customized facilities to meet customer demand quickly.
Track Jubilant Ingrevia — get its next earnings analysis in your feed
How does Jubilant Ingrevia rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Jubilant Ingrevia rank in Chemicals & Petrochemicals?
Compare Jubilant Ingrevia against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Jubilant Ingrevia's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…